Hypoxia in head and neck cancer
- 1 October 2006
- journal article
- review article
- Published by Oxford University Press (OUP) in The British Journal of Radiology
- Vol. 79 (946) , 791-798
- https://doi.org/10.1259/bjr/17904358
Abstract
A high level of hypoxia in solid tumours is an adverse prognostic factor for the poor outcome of cancer patients following treatment. This review describes the status of research into finding a practical method for measuring hypoxia and treating hypoxic tumours. The application of such methodology would enable the selection of head and neck cancer treatment based on an individual's tumour oxygenation status. This individualization would include the selection not only of surgery or radiotherapy, but also of novel hypoxia-modification strategies.Keywords
This publication has 72 references indexed in Scilit:
- Glucose requirement for hypoxic accumulation of hypoxia-inducible factor-1α (HIF-1α)Cancer Letters, 2005
- Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resectionEuropean Journal Of Cancer, 2004
- Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trialThe Lancet, 2003
- Pharyngocutaneous fistulaCurrent Opinion in Otolaryngology & Head and Neck Surgery, 2003
- Glucose Transporter 1 Gene Expression is Related to Thyroid Neoplasms with an Unfavorable Prognosis: An Immunohistochemical StudyThyroid®, 2002
- Hypoxia as a target for combined modality treatmentsEuropean Journal Of Cancer, 2002
- Gene transfer of antisense hypoxia inducible factor-1 α enhances the therapeutic efficacy of cancer immunotherapyGene Therapy, 2001
- Angiogenesis: How a Tumor Adapts to HypoxiaBiochemical and Biophysical Research Communications, 1999
- Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumoursNature, 1996